Importantly, as KIF4A inhibition can enhance the immune microenvironment (e.g., reducing MDSC infiltration), combining it with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) could represent an effective strategy to convert “cold” tumours into “hot” ones, thereby overcoming immunotherapy resistance [9]. Here, KIF4A is linked to neoplasm.